ImageneBio, Inc. Asset Resilience Ratio
ImageneBio, Inc. asset resilience ratio. ImageneBio, Inc. (IMA) has an Asset Resilience Ratio of 27.28% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of ImageneBio, Inc. to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ImageneBio, Inc. (2022–2025)
Asset resilience ratio of ImageneBio, Inc. from 2022 to 2025. This chart shows how ImageneBio, Inc.'s Asset Resilience Ratio has changed over time. Read ImageneBio, Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ImageneBio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ImageneBio, Inc. asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $41.48 Million | 27.28% |
| Total Liquid Assets | $41.48 Million | 27.28% |
Asset Resilience Insights
- Very High Liquidity: ImageneBio, Inc. maintains exceptional liquid asset reserves at 27.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ImageneBio, Inc. Industry Peers by Asset Resilience Ratio
Compare ImageneBio, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
ImageneBio, Inc. Asset Resilience Ratio by Year (2022–2025)
ImageneBio, Inc. asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for ImageneBio, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.68% | $40.82 Million | $152.98 Million | -33.38pp |
| 2024-12-31 | 60.06% | $84.99 Million | $141.51 Million | +31.13pp |
| 2023-12-31 | 28.93% | $55.57 Million | $192.09 Million | -27.40pp |
| 2022-12-31 | 56.33% | $97.03 Million | $172.26 Million | -- |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more